Apply Now
Dr. Fares Al-Ejeh
Senior Scientist
Educational Qualifications
Bachelor of Biotech (Honours)
Ph.D. (Cancer Biology)
Entity
Qatar Biomedical Research Institute
Division
Translational Oncology Research Center
Biography
Associate Professor Fares Al-Ejeh was awarded his Bachelor of Biotechnology degree, and his PhD from the University of Wollongong (NSW, Australia). His first post-doctoral position was industry-funded by Oncaidia Ltd at the Royal Adelaide Hospital/Hanson Institute. .
After five years in industry-oriented research, Dr. Al-Ejeh started his academic career at one of Australia's largest research institutes, the QIMR Berghofer Medical Research Institute. At QIMR, he established his own group, Personalised Medicine, in 2015. His track record includes two granted patents on Apomab and five submitted patent applications undergoing evaluation. He has more than 50 peer-reviewed publications focusing on cancer diagnostics and therapeutics with focus on translational medical research.
Dr. Al-Ejeh has contributed as a keynote speaker at several conferences and as a member of several panels for grant reviews in Australia and internationally. He is an Associate Member of the Australian Academy of Health and Medical Sciences (AAHMS) and an adjunct Associate Professor at the Faculty of Medicine, University of Queensland, Australia in recognition of his teaching and supervision of postgraduate students.
Bachelor of Biotech (Honours)
University of Wollongong (NSW/Australia)
2001
Ph.D. (Cancer Biology)
University of Wollongong (NSW/Australia)
2005
- Personalized/Precision Oncology
- Multi-omics
- Novel Biomarkers and Drug Targets
- Breast Cancer
Senior Scientist
Qatar Biomedical Research Institute/HBKU, Translational Oncology Research Center. Doha, Qatar.
2020 - present
Team Head (Faculty) and Senior Research Fellow
QIMR Berghhofer Medical Research Institute. Brisbane, Australia
2010 - 2019
Senior Researcher and Chief Scientific Officer
Oncaidia Ltd. and the Royal Adelaide Hospital, Hanson Institute. Adelaide, Australia
2005 - 2009
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications. 2022; 13, 946. https://doi.org/10.1038/s41467-022-28639-4 https://www.nature.com/articles/s41467-022-28639-4
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. NPJ Breast Cancer. 2022;8(1):57. https://doi.org/10.1038/s41523-022-00425-x https://pubmed.ncbi.nlm.nih.gov/35501337/
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clin Cancer Res. 2021;27(9):2624-2635. https://doi.org/10.1158/1078-0432.CCR-20-3463https://pubmed.ncbi.nlm.nih.gov/33589432/
A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer. bioRxiv 2021.03.23.436061; https://doi.org/10.1101/2021.03.23.436061 https://www.biorxiv.org/content/10.1101/2021.03.23.436061v1.abstract
G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. Theranostics. 2020;10(10):4515-4529. Published 2020 Mar 15. https://doi.org/10.7150/thno.41453 https://pubmed.ncbi.nlm.nih.gov/32292512/
Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. J Immunother Cancer. 2020;8(2):e001294. https://doi.org/10.1136/jitc-2020-001294 https://pubmed.ncbi.nlm.nih.gov/32948653/
Differential gene expression of tumor-infiltrating CD4+ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. Oncoimmunology. 2020;9(1):1825178. Published 2020 Sep 30. https://doi.org/10.1080/2162402X.2020.1825178 https://pubmed.ncbi.nlm.nih.gov/33101776/
Clinicopathologic significance of nuclear HER4 and phospho-YAP(S127) in human breast cancers and matching brain metastases. Ther Adv Med Oncol. 2020;12:1758835920946259. https://doi.org/10.1177/1758835920946259 https://pubmed.ncbi.nlm.nih.gov/33014146/
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019;10(1):1741. https://www.ncbi.nlm.nih.gov/pubmed/30988301
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight, 2019;5. pii: 124092. https://www.ncbi.nlm.nih.gov/pubmed/30830863
EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers (Basel), 2018 ;10(12). pii: E519. https://www.ncbi.nlm.nih.gov/pubmed/30562956
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018; 50(7):968-978. https://www.ncbi.nlm.nih.gov/pubmed/29915430
Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. Breast Cancer Res Treat, 2018;170(1):179-188. https://www.ncbi.nlm.nih.gov/pubmed/29468485
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. Breast Cancer Res Treat, 2018;167(1):289-301. https://www.ncbi.nlm.nih.gov/pubmed/28889351
Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage. American Journal of Human Genetics, 2017;101(2):255-266. https://www.ncbi.nlm.nih.gov/pubmed/28777932
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. Oncotarget, 2016, 13;7(37):60087-60100. https://www.ncbi.nlm.nih.gov/pubmed/27507046
Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis, 2014;3:e100. https://www.ncbi.nlm.nih.gov/pubmed/24752235
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 2014;20(12):3187-97. https://www.ncbi.nlm.nih.gov/pubmed/24838526
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget, 2014;5(10):3145-58. https://www.ncbi.nlm.nih.gov/pubmed/24762669
Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. Journal of Nuclear Medicine, 2014;55(5):772-9. https://www.ncbi.nlm.nih.gov/pubmed/24676755
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. Journal of Nuclear Medicine, 2013;54(6):913-21. https://www.ncbi.nlm.nih.gov/pubmed/23564760
All publications at https://www.ncbi.nlm.nih.gov/pubmed/?term=al-ejeh
- 2016 - Certificate of Excellence in Reviewing, Oncology Reports Journal - Spandidos Publications (Athens/Greece)
- 2016 - Commendation Letter for Outstanding Contribution to Institutional Animal Ethics Committee, QIMRB Medical Research Institute (Brisbane, Australia)
- 2016 - Outstanding External Assessor Contribution to NH&MRC Honour Roll 2016, Australian National Health & Medical Research Council (Canberra, Australia)
- 2014 - Commendation Letter for insightful oral presentation as a keynote speaker at the Australian and New Zealand Society of Nuclear Medicine, Australian and New Zealand Society of Nuclear Medicine (ANZSNM, Australia)
- 2008 - Asia-Pacific Frost & Sullivan Technology Innovation Award For APOMAB innovation in Oncaidia Ltd., Frost & Sullivan (Santa Clara, California)
- 2003 - ASMR Young Investigator Award, Australian Society for Medical Research (ASMR, Australia)